炎症性肠病患者启动生物制剂后肠切除与结肠切除术的发生率:一项队列研究
基于美国26个医疗系统的电子健康记录数据库,纳入2015至2020年诊断为克罗恩病或溃疡性结肠炎并接受生物制剂治疗的患者。生物制剂治疗的克罗恩病患者肠切除率(9.3%)显著低于未接受生物制剂者(12.1%),溃疡性结肠炎患者结肠切除术率(7.3%)也显著低于未接受生物制剂者(11.0%)。结论提示生物制剂可能影响炎症性肠病的手术率。
要点
- 生物制剂治疗的克罗恩病患者肠切除率为9.3%,低于未治疗者的12.1%(p < .001)。
- 生物制剂治疗的溃疡性结肠炎患者结肠切除术率为7.3%,低于未治疗者的11.0%(p < .001)。
- 吸烟、艰难梭菌感染和肛周病变与克罗恩病肠切除相关;结肠肿瘤和艰难梭菌感染与溃疡性结肠炎结肠切除相关。
核心结论
- 在这项基于大型医疗行政数据库的研究中,接受生物制剂治疗的炎症性肠病患者接受肠切除的可能性显著低于从未接受生物制剂者。
- 该数据提示生物制剂可能影响炎症性肠病的手术率。
研究设计与样本
- 研究使用商业数据库(Explorys Inc,克利夫兰,俄亥俄州),包含来自美国26个大型整合医疗系统的电子健康记录数据。
- 研究纳入2015年至2020年间诊断为克罗恩病或溃疡性结肠炎并接受任何生物制剂治疗的所有患者。
- 主要结局为检查生物制剂治疗与肠切除患病率之间的关联,同时识别接受生物制剂的炎症性肠病患者中与手术相关的因素。
主要发现
- 在数据库32,904,480名患者中,识别出140,540例克罗恩病患者和115,260例溃疡性结肠炎患者,其中分别有25,840例(18%)和9,050例(7.8%)接受了生物制剂。
- 生物制剂治疗的克罗恩病患者肠切除患病率(9.3%)显著低于未接受生物制剂者(12.1%)(p < .001)。
- 生物制剂治疗的溃疡性结肠炎患者接受结肠切除术的可能性(7.3%)显著低于未接受生物制剂治疗者(11.0%)(p < .001)。
- 吸烟、艰难梭菌感染和肛周病变与克罗恩病中的肠切除相关。
- 结肠肿瘤和艰难梭菌感染与溃疡性结肠炎中的结肠切除相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: 50% to 80% Crohn's disease (CD) and 10% to 30% ulcerative colitis (UC) patients require surgery over their lifetime. Biologic therapies may alter this natural history, but data on the effect of biologics on surgery rates in this patient population are mixed. We sought to investigate the influence of biologics on surgery prevalence in CD and UC. METHODS: We used a commercial database (Explorys Inc, Cleveland, OH), which includes electronic health record data from 26 major integrated US healthcare systems. We identified all patients who were diagnosed with CD or UC that were treated with any biologics between 2015 and 2020. The primary outcome was to examine the association between biologics therapy and the prevalence of bowel resection. Also, we identified the factors associated with surgery in IBD patients on biologics. RESULTS: Of 32,904,480 patients in the database, we identified 140,540 patients with CD and 115,260 patients with UC, of whom 25,840 (18%) and 9,050 (7.8%) patients received biologics, respectively. The prevalence of intestinal resection was significantly lower in biologics-treated CD patients (9.3%) compared to those who did not receive biologics (12.1%) (p < .001). Similarly, biologic-treated UC patients were significantly less likely to undergo colectomy (7.3%) compared to UC patients who did not receive biologic therapy (11.0%) (p < .001). Tobacco use, Clostridium difficile infection, and perianal disease were associated with intestinal resection in CD. Colon neoplasm and Clostridium difficile infection were associated with colectomy in UC. CONCLUSIONS: In this study of a large healthcare administrative database, inflammatory bowel disease (IBD) patients treated with biologics were significantly less likely to undergo bowel resection when compared to those who never received biologics. This data suggests that biologics may impact surgical rates in IBD.
引用
- Khoudari G, Mansoor E, Click B, et al. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study. Clin Gastroenterol Hepatol. 2020. PMID: 33065311. doi:10.1016/j.cgh.2020.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。